MAPK3 and neoplasm: Constitutive activation of ERK1/2 was also observed in V2O5-induced mouse carcinomas from the NTP study containing both K-ras mutations and loss of heterozygosity [85], which supports findings in this model and suggests involvement of ERK1/2 as one pathway driving tumor promotion by V2O5.